Reaxys Announces Winners of the 2013 Reaxys PhD Prize
Neuchâtel, Switzerland, July 3, 2013
The Reaxys PhD Prize awards original and innovative research in organic,
organometallic and inorganic chemistry
The Reaxys PhD Prize awards original and innovative research in organic, organometallic and inorganic chemistry
Reaxys®, a unique workflow solution for chemistry research, has today announced the winners of the 2013 Reaxys PhD Prize. Awarding innovative and original research in organic, organometallic and inorganic chemistry, the Reaxys PhD Prize celebrates top research conducted by leading young chemists across the globe.
The 2013 Reaxys PhD Prize Winners are:
- Martin Donakowski from the Poeppelmeier group at Northwestern University, USA
- Max Hansmann from the Hashmi group at University of Heidelberg, Germany
- Johannes Heppekausen from the Fürstner group at the Max-Planck Institute, Mülheim, Germany
The winners were
selected from 45 finalists by the Chairs of the Reaxys PhD Prize's review board:
Professors Tony Barrett (Imperial College London, UK), Eiichi Nakamura (University
of Tokyo, Japan), Gerard Parkin (Columbia University, New York, USA), Martin
Jansen (Max-Planck Institute, Stuttgart, Germany), Barry Trost (Stanford
University, USA) and Henry Wong (Chinese University Hong Kong, Hong Kong).
"Since its inception in 2010 there has been an ever increasing number of superb applications for the Reaxys PhD Prize. Whilst this has provided the review board with an immense task of selecting the top three candidates, their efforts have been rewarded by the delight of reading such elegant creative synthetic chemistry," said Professor Barrett. There is no doubt that the future global strength of chemistry is securely based on a cohort of outstanding young scientists, who are all a credit to our subject and to their own universities. I look forward to personally interacting with members of the Reaxys Prize Club, a most select society."
This year a record of 581 submissions were received from nearly 400 universities across the globe. Submissions consisted of a representative, peer-reviewed published research paper accompanied by a PhD's supervisor recommendation letter and CV. Entries were closely scrutinized by a review board of over 100 international chemists from academia and industry. The reviewers judged the entries for originality, innovation, importance to the field, applicability, rigor of approach and publication quality.
The three winners and 42 remaining finalists have been invited to attend the Reaxys Inspiring Chemistry Conference which will be held in Grindelwald, Switzerland, September 22 – 24, 2013 where they will be given the opportunity to present their research.
For more information about the Reaxys PhD Prize and Chemistry Conference go to: http://inspiringchemistry.reaxys.com/phdprize ; http://inspiringchemistry.reaxys.com/conference
For more information about Reaxys go to www.elsevier.com/reaxys
# # #
Reaxys® is a workflow solution for research chemists. Offering a wealth of experimentally validated information, Reaxys® combines reaction and substance data in organic, organometallic, inorganic and physical chemistry with synthesis planning. Researchers can get the information they need in a single overview, from source publications carefully selected for their importance and relevance to research chemists. Elsevier continues to engage with the chemistry community to ensure that Reaxys® continues to reflect how chemists think and work. For more information please visit Reaxys.
Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
About Reed Elsevier Properties SA
Reed Elsevier Properties SA is a centre of excellence within Reed Elsevier for the management, development and protection of intellectual property. Reed Elsevier Properties SA owns the PharmaPendium and Reaxys databases. Trademarks including Reaxys®, PharmaPendium®, Targetinsights™, The Lancet® and World Travel Market® are owned and protected by Reed Elsevier Properties SA and used under licence.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+31 20 485 2247